Mercury Biopharmaceutical Corporation (6932.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan
Mercury Biopharmaceutical Corporation financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 4.96 m TWD | 0.00 TWD |
| Gross profit | 4.18 m TWD | 0.00 TWD |
| Operating income | -54.04 m TWD | -68.55 m TWD |
| EBIT | -49.73 m TWD | -66.27 m TWD |
| Net income | -50.57 m TWD | -67.23 m TWD |
| Diluted EPS – continuing operations | -0.12 TWD | -0.16 TWD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Mercury Biopharmaceutical Corporation
Merdury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development technology platform that integrates drug formulation, 3D powder printing, and hardware and software technologies to create drug-specific 3D printing production equipment, which can be used as a foundation for pharmaceutical companies to provide hosted services and in-house product development. It also offers formulation design and 3D pharmaceutical processing services. Merdury Biopharmaceutical Corporation was founded in 2019 and is headquartered in New Taipei City, Taiwan.
More stocks
- Hyundai E P (089470.KS)
- Taiwan Bio Therapeutics Co., Ltd (6892.TWO)
- Daelim Paper Co.Ltd (017650.KQ)
- Halla Eng&Cons (014790.KS)
- Woosu AMS Co.Ltd (066590.KQ)
- P.A. Resources Bhd (7225.KL)
- Mindax Ltd (MDX.AX)
- Rans Entertainmen Indonesia Tbk (RANS.JK)
- Ni Steel (008260.KS)
- Graphene & Solar Technologies Ltd (GSTX)
- Ko Ja Cayman Co Ltd (5215.TW)
- Shareholder Value Beteiligungen AG (SVE.DE)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.